TomoTherapy unveils TomoDirect
TomoTherapy introduced its TomoDirect, a non-rotational treatment option for the Hi-Art system, at the 50th annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Boston, held Sept. 22-25.
TomoDirect, which received FDA 510(k) clearance in late August, was developed as clinical component of the TomoHelical delivery mode, allowing users to plan and treat routine cases, while maintaining the quality of the beamlet-based delivery, according to the Madison, Wis.-based company.
TomoDirect will use the power of the platform that makes the helical TomoTherapy successful, according to Thomas Mackie, PhD, co-founder of TomoTherapy. “We expect treatment planning will be dramatically reduced due to the much smaller number of beam directions used. Furthermore, for certain geometrics, the ability to use only the most beneficial angles will cut delivery times significantly,” he said.
With TomoDirect, the user can choose up to 12 discrete angles for optimal target coverage; define a modulation level, or opt for tissue-compensated 3D conformal delivery; treatment planning with the power of the Hi-Art computing platform applied to a small number of beams; and deliver all beams for each target, sequentially, with one turn of the operator console key, TomoTherapy said.
“Now we will have an option to deliver dose vie two unique and complementary delivery modes, choosing whichever provides the optimal dose distribution, according to Paul Read, MD, PhD, from the University of Virginia in Charlottesville. “TomoDirect will expand the spectrum of external beam radiation therapy patients who can be treated with TomoTherapy’s image-guided intensity-modulated radiation therapy,” Read added.
Read said that “breast cancer patients will benefit from TomoDirect, and other disease sites will likely be developed for which there is clinical benefit.”
The treatment couch passes through the bore of the system during a TomoDirect delivery, making it possible for users to treat a target volume up to 160 cm with no need to reposition the patient, and no field junction required.
TomoDirect, which received FDA 510(k) clearance in late August, was developed as clinical component of the TomoHelical delivery mode, allowing users to plan and treat routine cases, while maintaining the quality of the beamlet-based delivery, according to the Madison, Wis.-based company.
TomoDirect will use the power of the platform that makes the helical TomoTherapy successful, according to Thomas Mackie, PhD, co-founder of TomoTherapy. “We expect treatment planning will be dramatically reduced due to the much smaller number of beam directions used. Furthermore, for certain geometrics, the ability to use only the most beneficial angles will cut delivery times significantly,” he said.
With TomoDirect, the user can choose up to 12 discrete angles for optimal target coverage; define a modulation level, or opt for tissue-compensated 3D conformal delivery; treatment planning with the power of the Hi-Art computing platform applied to a small number of beams; and deliver all beams for each target, sequentially, with one turn of the operator console key, TomoTherapy said.
“Now we will have an option to deliver dose vie two unique and complementary delivery modes, choosing whichever provides the optimal dose distribution, according to Paul Read, MD, PhD, from the University of Virginia in Charlottesville. “TomoDirect will expand the spectrum of external beam radiation therapy patients who can be treated with TomoTherapy’s image-guided intensity-modulated radiation therapy,” Read added.
Read said that “breast cancer patients will benefit from TomoDirect, and other disease sites will likely be developed for which there is clinical benefit.”
The treatment couch passes through the bore of the system during a TomoDirect delivery, making it possible for users to treat a target volume up to 160 cm with no need to reposition the patient, and no field junction required.